血液DNA甲基化标志物与晚发型阿尔茨海默病的关联:一种潜在的诊断方法
本研究为病例对照研究,纳入80例 probable AD 痴呆患者与100例年龄和性别匹配的认知健康对照,检测46个胞嘧啶-鸟嘌呤位点DNA甲基化水平及血浆pTau181。包含NXN、ABCA7、HOXA3基因甲基化水平与血浆pTau181的组合模型在调整年龄、性别和APOE ɛ4基因型后,诊断性能显著优于单一pTau181模型,受试者工作特征曲线下面积为0.93(95%CI 0.89-0.97),敏感度83.30%、特异度90.00%。
要点
- 血液DNA甲基化标志物组合联合血浆pTau181可提高晚发型阿尔茨海默病的诊断准确性。
- 该组合模型受试者工作特征曲线下面积为0.93(95%CI 0.89-0.97),敏感度83.30%、特异度90.00%。
- 性别分层分析中,HOXA3 DNA甲基化水平与阿尔茨海默病保持一致性关联。
核心结论
- 血液DNA甲基化标志物对阿尔茨海默病无创诊断具有潜在转化价值。
研究设计与样本
- 病例对照研究,纳入80例符合2011年美国国家老龄研究所与阿尔茨海默病协会指南的 probable AD 痴呆患者和100例年龄及性别匹配的认知健康对照,对照来自西班牙纳瓦拉大学医院神经内科,采用方便抽样。
- 通过亚硫酸氢盐焦磷酸测序检测46个胞嘧啶-鸟嘌呤位点(经全面文献检索选出的21个基因)的血液DNA甲基化水平,并用Simoa技术测定血浆pTau181水平。
- 采用多变量逻辑回归分析探索区分阿尔茨海默病患者与对照的最佳模型,并按性别进行分层分析。
主要发现
- AD患者年龄中位数(四分位距)为79(11)岁,女性占58.8%;认知健康对照年龄为77(10)岁,女性占58%。
- 包含NXN、ABCA7和HOXA3基因DNA甲基化水平及血浆pTau181的组合模型,在调整年龄、性别和APOE ɛ4基因型后,受试者工作特征曲线下面积为0.93(95%CI 0.89-0.97),显著优于单一pTau181模型。
- 该组合模型的敏感度为83.30%,特异度为90.00%。
- 性别分层分析后,HOXA3 DNA甲基化水平与AD保持一致性关联。
关键数值与推荐
- AD诊断依据2011年美国国家老龄研究所与阿尔茨海默病协会指南的 probable AD 痴呆标准。
- 组合模型受试者工作特征曲线下面积0.93(95%CI 0.89-0.97),敏感度83.30%,特异度90.00%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: There is an urgent need to identify novel noninvasive biomarkers for Alzheimer disease (AD) diagnosis. Recent advances in blood-based measurements of phosphorylated tau (pTau) species are promising but still insufficient to address clinical needs. Epigenetics has been shown to be helpful to better understand AD pathogenesis. Epigenetic biomarkers have been successfully implemented in other medical disciplines, such as oncology. The objective of this study was to explore the diagnostic accuracy of a blood-based DNA methylation marker panel as a noninvasive tool to identify patients with late-onset Alzheimer compared with age-matched controls. METHODS: A case-control study was performed. Blood DNA methylation levels at 46 cytosine-guanine sites (21 genes selected after a comprehensive literature search) were measured by bisulfite pyrosequencing in patients with "probable AD dementia" following National Institute on Aging and the Alzheimer's Association guidelines (2011) and age-matched and sex-matched controls recruited at Neurology Department-University Hospital of Navarre, Spain, selected by convenience sampling. Plasma pTau181 levels were determined by Simoa technology. Multivariable logistic regression analysis was performed to explore the optimal model to discriminate patients with AD from controls. Furthermore, we performed a stratified analysis by sex. RESULTS: The final study cohort consisted of 80 patients with AD (age: median [interquartile range] 79 [11] years; 58.8% female) and 100 cognitively healthy controls (age 77 [10] years; 58% female). A panel including DNA methylation levels at NXN, ABCA7, and HOXA3 genes and plasma pTau181 significantly improved (area under the receiver operating characteristic curve 0.93, 95% CI 0.89-0.97) the diagnostic performance of a single pTau181-based model, adjusted for age, sex, and APOE ɛ4 genotype. The sensitivity and specificity of this panel were 83.30% and 90.00%, respectively. After sex-stratified analysis, HOXA3 DNA methylation levels showed consistent association with AD. DISCUSSION: These results highlight the potential translational value of blood-based DNA methylation biomarkers for noninvasive diagnosis of AD. REGISTRATION INFORMATION: Research Ethics Committee of the University Hospital of Navarre (PI17/02218).
引用
- Acha B, Corroza J, Sánchez-Ruiz de Gordoa J, et al. Association of Blood-Based DNA Methylation Markers With Late-Onset Alzheimer Disease: A Potential Diagnostic Approach. Neurology. 2023. PMID: 37827850. doi:10.1212/WNL.0000000000207865
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。